Objective: To assess the efficacy of anti-xerostomic topical medication (urea 10%) in patients with burning mouth syndrome (BMS). Method: Thirty-eight subjects diagnosed with BMS according to the International Association for the Study of Pain guidelines were randomized to either placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben, and 10% glycerol in distilled water qsp 100 g) or treatment (urea 10%) to be applied to the oral cavity 3-4 times per day for 3 months. The patients were evaluated before and after treatment with the following instruments: the EDOF-HC protocol (Orofacial Pain Clinic - Hospital das Clínicas), a xerostomia questionnaire, and quantitative sensory testing. Results: There were no differences in salivary flow or gustative, olfactory, or sensory thresholds (P>0.05). Fifteen (60%) patients reported improvement with the treatments (P=0.336). Conclusion: In conclusion, there were no differences between groups, and both exhibited an association between reported improvement and salivation.
CITATION STYLE
da Silva, L. A., de Siqueira, J. T. T., Teixeira, M. J., & de Siqueira, S. R. D. T. (2014). The role of xerostomia in burning mouth syndrome: A case-control study. Arquivos de Neuro-Psiquiatria, 72(2), 91–98. https://doi.org/10.1590/0004-282X20130218
Mendeley helps you to discover research relevant for your work.